Tags

Type your tag names separated by a space and hit enter

CGRP Monoclonal Antibodies for the Preventative Treatment of Migraine.
Curr Pain Headache Rep. 2018 Apr 06; 22(5):38.CP

Abstract

PURPOSE OF REVIEW

CGRP is a key neuropeptide in migraine pathophysiology. The blockade of the CGRP pathway at the side of the CGRP receptor of the CGRP peptide leads to the interruption of trigeminal nerve system-mediated headache syndromes such as migraine. Monoclonal antibodies (mAbs) targeting the CGRP pathway have been developed and are currently under investigation for episodic (EM) and chronic migraine (CM) prevention. Here, we report data from these clinical trials.

RECENT FINDINGS

Placebo-controlled, randomized double-blind phase studies of CGRP mAbs in episodic and chronic migraine have shown that the specific blockade of the peptide or the CGRP receptor are both powerful mechanisms to reduce migraine frequency. Along with the reduction of acute migraine-specific medication intake, early onset of efficacy of mAbs has been demonstrated. Most common adverse events are injection sider reactions. Depending on the mAb, the administration mode is a monthly or even less frequently s.c. or I.V. formulation. Phase II studies in EM and CM demonstrate that CGRP mAbs are effective anti-migraine preventatives with a beneficial adverse event profile. Further detailed results from larger phase III clinical trials are expected soon.

Authors+Show Affiliations

Charité Universitätsmedizin Berlin, Department of Neurology, Charité Headache Center, Charitéplatz 1, 10117, Berlin, Germany.Charité Universitätsmedizin Berlin, Department of Neurology, Charité Headache Center, Charitéplatz 1, 10117, Berlin, Germany.Charité Universitätsmedizin Berlin, Department of Neurology, Charité Headache Center, Charitéplatz 1, 10117, Berlin, Germany. uwe.reuter@charite.de.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

29623520

Citation

Israel, Heike, et al. "CGRP Monoclonal Antibodies for the Preventative Treatment of Migraine." Current Pain and Headache Reports, vol. 22, no. 5, 2018, p. 38.
Israel H, Neeb L, Reuter U. CGRP Monoclonal Antibodies for the Preventative Treatment of Migraine. Curr Pain Headache Rep. 2018;22(5):38.
Israel, H., Neeb, L., & Reuter, U. (2018). CGRP Monoclonal Antibodies for the Preventative Treatment of Migraine. Current Pain and Headache Reports, 22(5), 38. https://doi.org/10.1007/s11916-018-0686-4
Israel H, Neeb L, Reuter U. CGRP Monoclonal Antibodies for the Preventative Treatment of Migraine. Curr Pain Headache Rep. 2018 Apr 6;22(5):38. PubMed PMID: 29623520.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - CGRP Monoclonal Antibodies for the Preventative Treatment of Migraine. AU - Israel,Heike, AU - Neeb,Lars, AU - Reuter,Uwe, Y1 - 2018/04/06/ PY - 2018/4/7/entrez PY - 2018/4/7/pubmed PY - 2018/10/3/medline KW - Antibody safety KW - CGRP antibody KW - Chronic migraine KW - Episodic migraine KW - Migraine prevention SP - 38 EP - 38 JF - Current pain and headache reports JO - Curr Pain Headache Rep VL - 22 IS - 5 N2 - PURPOSE OF REVIEW: CGRP is a key neuropeptide in migraine pathophysiology. The blockade of the CGRP pathway at the side of the CGRP receptor of the CGRP peptide leads to the interruption of trigeminal nerve system-mediated headache syndromes such as migraine. Monoclonal antibodies (mAbs) targeting the CGRP pathway have been developed and are currently under investigation for episodic (EM) and chronic migraine (CM) prevention. Here, we report data from these clinical trials. RECENT FINDINGS: Placebo-controlled, randomized double-blind phase studies of CGRP mAbs in episodic and chronic migraine have shown that the specific blockade of the peptide or the CGRP receptor are both powerful mechanisms to reduce migraine frequency. Along with the reduction of acute migraine-specific medication intake, early onset of efficacy of mAbs has been demonstrated. Most common adverse events are injection sider reactions. Depending on the mAb, the administration mode is a monthly or even less frequently s.c. or I.V. formulation. Phase II studies in EM and CM demonstrate that CGRP mAbs are effective anti-migraine preventatives with a beneficial adverse event profile. Further detailed results from larger phase III clinical trials are expected soon. SN - 1534-3081 UR - https://www.unboundmedicine.com/medline/citation/29623520/CGRP_Monoclonal_Antibodies_for_the_Preventative_Treatment_of_Migraine_ L2 - https://dx.doi.org/10.1007/s11916-018-0686-4 DB - PRIME DP - Unbound Medicine ER -